company background image
1312 logo

Kontafarma China Holdings SEHK:1312 Stock Report

Last Price

HK$0.028

Market Cap

HK$150.9m

7D

-15.2%

1Y

-24.3%

Updated

23 Dec, 2024

Data

Company Financials

Kontafarma China Holdings Limited

SEHK:1312 Stock Report

Market Cap: HK$150.9m

1312 Stock Overview

An investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. More details

1312 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Kontafarma China Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kontafarma China Holdings
Historical stock prices
Current Share PriceHK$0.028
52 Week HighHK$0.048
52 Week LowHK$0.026
Beta0.060
1 Month Change-9.68%
3 Month Change-9.68%
1 Year Change-24.32%
3 Year Change-41.67%
5 Year Change-82.72%
Change since IPO-87.16%

Recent News & Updates

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Dec 20
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Oct 09
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Recent updates

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Dec 20
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Oct 09
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31
Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

May 24
There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

Dec 28
Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Sep 01
Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Dec 29
Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15
Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20
Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04
Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18
Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07
These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Shareholder Returns

1312HK PharmaceuticalsHK Market
7D-15.2%-1.9%-0.5%
1Y-24.3%-3.9%19.9%

Return vs Industry: 1312 underperformed the Hong Kong Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 1312 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 1312's price volatile compared to industry and market?
1312 volatility
1312 Average Weekly Movement10.5%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1312 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1312's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993717Feifei Wangwww.kontafarma.com.hk

Kontafarma China Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. It operates in Pharmaceutical Business and Fitness Business segments. The company offers chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers; operates in the franchise business; and provides consultation services for fitness and health activities.

Kontafarma China Holdings Limited Fundamentals Summary

How do Kontafarma China Holdings's earnings and revenue compare to its market cap?
1312 fundamental statistics
Market capHK$150.89m
Earnings (TTM)-HK$63.24m
Revenue (TTM)HK$836.92m

0.2x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1312 income statement (TTM)
RevenueHK$836.92m
Cost of RevenueHK$335.76m
Gross ProfitHK$501.16m
Other ExpensesHK$564.40m
Earnings-HK$63.24m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.011
Gross Margin59.88%
Net Profit Margin-7.56%
Debt/Equity Ratio4.1%

How did 1312 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kontafarma China Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution